Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (The EMPA-KIDNEY Collaborative Group The Lancet 2023)
🤔 EMPA Kidney sub-group analysis by DM and ACR status
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (The EMPA-KIDNEY Collaborative Group 2023)
🤔 Albuminuria reduction drives Finerenone's kidney benefit
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes (Agarwal et al, Annals IM 2023)
Two’s Company but Three maybe the Winner? Aldosterone Synthase Inhibition added to RASi + Flozin
Zibotentan and Flozins: Climbing to the ZENITH of nephroprotection?
Closed Loop Sugar Control: The Visual Abstract
Brilliant VA by Sharanya Ramesh for this week’s NephJC on safety and efficacy of fully closed-loop insulin therapy in patients with type 2 diabetes requiring dialysis.
Visual abstract for FIDELIO
Beautiful visual abstract by Dhwanil Patel